Clinical Trials Sponsored by FDC Foundation

Total 16207 results

Research Foundation for Mental Hygiene, Inc.
FDC Foundation

Completed

Disulfiram: A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease

Quality of Life | Fatigue

United States
Lawson Health Research Institute
McMaster University; FDC Foundation

Withdrawn

Neurofeedback Effectiveness Trial in PTSD

PTSD | Cognitive Dysfunction | Cognitive Deficit | Post-traumatic Stress Disorder

Canada
University of Pittsburgh
CDC Foundation

Completed

STD Testing in Outpatient Practices (STOP)

STD

United States
Lawson Health Research Institute
Canadian Institutes of Health Research (CIHR); FDC Foundation

Withdrawn

Goal Management Training in Individuals With PTSD

PTSD | Cognitive Impairment | Cognitive Dysfunction | Cognitive Deficit | Post-traumatic Stress Disorder

Canada
New York University
Aliko Dangote Foundation; Nigerian Institute of Medical Research; CDC Foundation

Recruiting

The CircumVent Project: A CPAP/O2 Helmet Solution for Non-Invasive Ventilation Among Patients With COVID-19 (CircumVent)

SARS-CoV-2 Acute Respiratory Disease | COVID-19 Respiratory Infection

Nigeria
CDC Foundation
Gilead Sciences

Unknown

Sustainable Healthcenter Implementation PrEP Pilot Study (SHIPP)

HIV Preexposure Prophylaxis | HIV Chemoprophylaxis

United States
JDC Tech

Completed

Clinical Study to Evaluate of The Whitening Efficacy and Safety of REMEWHITE (REMEWHITE)

Tooth Whitening

Korea, Republic of
Retina Foundation of the Southwest

Completed

Study of Docosahexaenoic Acid (DHA) Supplementation in Patients With X-Linked Retinitis Pigmentosa

Retinitis Pigmentosa
PTC Therapeutics
Cystic Fibrosis Foundation; FDA Office of Orphan Products Development

Completed

PTC124 for Cystic Fibrosis

Cystic Fibrosis

United States
ADC Therapeutics S.A.

Recruiting

A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

Advanced Solid Tumors

United States, United Kingdom, Spain, France
ADC Therapeutics S.A.

Recruiting

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5)

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

Japan, Belgium, France, Italy, Spain, United Kingdom, United States, Israel, Hungary, Brazil, Switzerland, Poland, Canada, Puerto Rico, Czechia, Netherlands, China, Mexico, Argentina, Chile, Turkey
ADC Therapeutics S.A.

Completed

Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Refractory Hodgkin Lymphoma | Relapsed Hodgkin Lymphoma

United States, Spain, United Kingdom, Poland, Belgium, Hungary, Germany, France, Italy, Czechia, Canada
ADC Therapeutics S.A.

Terminated

Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma

United States, Spain, United Kingdom, France, Italy, Belgium
ADC Therapeutics S.A.

Terminated

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma (LOTIS-6)

Relapsed Follicular Lymphoma | Refractory Follicular Lymphoma

United States, Belgium, Hungary, Israel, Spain, Switzerland, Poland, France, United Kingdom, Italy
ADC Therapeutics S.A.

Completed

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS-2)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B-Cell Lymphoma Refractory

United States, United Kingdom, Italy, Switzerland
ADC Therapeutics S.A.

Terminated

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Bladder Cancer | Non-small Cell Lung Cancer | Pancreas Cancer | Colo-rectal Cancer | Triple-negative Breast Cancer | Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content | Head and Neck...

United States, Belgium, United Kingdom
ADC Therapeutics S.A.

Terminated

Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors

Advanced Solid Tumors

United States
ADC Therapeutics S.A.

Recruiting

A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

Diffuse Large B-Cell Lymphoma | High-grade B-cell Lymphoma

Taiwan, Korea, Republic of, United States, Brazil
ADC Therapeutics S.A.

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors

Advanced Solid Tumors

United States, Spain, United Kingdom
ADC Therapeutics S.A.

Completed

Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

Hodgkin Lymphoma | Non-Hodgkin Lymphoma

United States, United Kingdom
ADC Therapeutics S.A.

Terminated

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Acute Lymphoblastic Leukemia

United States
ADC Therapeutics S.A.

Completed

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Mantle-Cell | Waldenstrom Macroglobulinemia | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Primary Mediastinal B-cell Lymphoma | Burkitt's Lymphoma | Lymphoma, Marginal Zone

United Kingdom, United States, Italy
ADC Therapeutics S.A.

No longer available

Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
PDC Biotech GmbH

Completed

Dose-Finding Study of PDC31 in Patients With Primary Dysmenorrhea

Dysmenorrhea

Austria, Germany
ADC Therapeutics S.A.

Recruiting

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

B-Cell Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed B-Cell Non-Hodgkin Lymphoma

United States, Spain, Italy, United Kingdom, Belgium, Czechia
ADC Therapeutics S.A.

Completed

A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)

Diffuse Large B-cell Lymphoma

Spain, United States, Italy, Puerto Rico
ADC Therapeutics S.A.

Withdrawn

Long-term Registry of Patients Treated With Loncastuximab Tesirine

B-Cell Lymphomas

United States
ADC Therapeutics S.A.

Withdrawn

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) (LOTIS-8)

Diffuse Large B-Cell Lymphoma

United States
ADC Therapeutics S.A.

Terminated

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma

Spain, United States
ADC Therapeutics S.A.

Terminated

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

Breast Cancer | Non Small Cell Lung Cancer | Bladder Cancer | GastroEsophageal Cancer

United States, Belgium
ADC Therapeutics S.A.

Terminated

Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia

United States
RDC Clinical Pty Ltd

Recruiting

Effect of Maolactin on Gastrointestinal Tract (GIT) Health

Gastrointestinal Dysfunction

Australia
RDC Clinical Pty Ltd

Recruiting

Effectiveness of Testofen Compared to Placebo on Long COVID Symptoms

Long Covid19

Australia
RDC Clinical Pty Ltd

Withdrawn

Effect of Fenugreek Fibre on Gut Microbiome

Gut Microbiome

Australia
RDC Clinical Pty Ltd

Completed

The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema

Eczema, Atopic

Australia
RDC Clinical Pty Ltd

Completed

A Study to Determine Optimal Absorption of Single Dose Omega-3

Optimal Gastrointestinal Absorption of Omega-3

Australia
RDC Clinical Pty Ltd

Not yet recruiting

Effect of Topical PlexoZome® Levagen® Spray on Relief of Post Exercise Knee Joint Pain

Knee Joint Pain

Australia
RDC Clinical Pty Ltd

Not yet recruiting

Safety and Effectiveness of IHAT in Iron Deficient Pre-menopausal Woman

Iron-deficiency

Australia
RDC Clinical Pty Ltd

Completed

A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines.

Migraine

Australia
PDC*line Pharma SAS

Active, not recruiting

Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

Non Small Cell Lung Cancer

Belgium, France, Netherlands, Germany, Poland
RDC Clinical Pty Ltd

Recruiting

Comparison of 2 Extracts of Saw Palmetto Versus Placebo on BPH Symptoms

Benign Prostatic Hyperplasia

Australia
RDC Clinical Pty Ltd

Recruiting

Effectiveness of PEA Compared to Placebo on Acute Menstrual Pain

Menstrual Pain

Australia
RDC Clinical Pty Ltd

Recruiting

Effect of Testofen on Erectile Function in an Adult Male Population

Erectile Dysfunction

Australia
RDC Clinical Pty Ltd

Completed

The Effectiveness of a Caralluma Fimbriata Extract on Stress, Sleep and Neurotransmitters

Stress | Sleep

Australia
RDC Clinical Pty Ltd

Completed

Effectiveness of Food-grown Magnesium on Sleep Quality/Quantity

Sleep

Australia
Fundacion Miguel Servet
Hospital Universitario Getafe; Matia Foundation

Unknown

Impact of a Multicomponent Exercise Program on Functional Capacity in Frail Aged Participants With Cognitive Decline

Cognitive Impairment | Frail Elderly Syndrome

Spain
Calmy Alexandra
University Hospital, Geneva; Swiss National Science Foundation; Swiss Heart Foundation and other collaborators

Terminated

ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART (NILACH)

Atherosclerosis | HIV

Switzerland
University Hospital, Basel, Switzerland
Swiss Agency for Development and Cooperation (SDC); World Diabetes Foundation...

Recruiting

"Community-based, eHealth Supported Management of Cardiovascular Risk Factors by Lay Village Health Workers (ComBaCaL aHT TwiC 1 & ComBaCaL aHT TwiC 2)

Arterial Hypertension

Lesotho, Switzerland
Food and Drug Administration (FDA)

Completed

Human Perception on Medical Extended Reality Devices

Healthy

United States
University Children's Hospital Basel
Swiss National Science Foundation; Fondation Botnar

Completed

Measurement of Lipogenic Flux by Deuterium Resolved Mass Spectrometry Via Non-invasive Breath Analysis (D2OBREATH)

De Novo Lipogenesis (DNL)

Switzerland

Clinical Trials Sponsored by FDC Foundation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations